Young streak off a low base: a short run of consecutive-period improvement has just started, after a stretch that gave i
The model's full reasoning — Q1 2016 call → NOWe need to determine if management conveys a young run of consecutive improvements in a part of the business that had been unimpressive, with causes attached to the company and still in force. The transcript covers Q1 2016 earnings call. The company is Curis, a biotech. They discuss CUDC-907, CA170, and Erivedge. The financial results: net loss of $9.4 million in Q1 2016 vs $31.8 million in Q1 2015. But that prior year loss included a one-time charge of $24.3 million for in-process R&D. So the improvement in net loss is largely due to that one-time charge. Revenues were $1.7 million for both Q1 2016 and Q1 2015. So revenues flat. Operating expenses: $10.5 million in Q1 2016 vs $32.7 million in Q1 2015, but again that includes the one-time charge. R&D expenses increased from $4.7 million to $6.8 million. G&A increased slightly. So the financials are not showing a run of improvement; revenues flat, expenses up, net loss improved only due to one-time charge. The call is about clinical progress, not financial performance. The question asks: "does management convey that the business has NOW PUT TOGETHER A SHORT, STILL-YOUNG RUN OF CONSECUTIVE PERIODS OF REAL IMPROVEMENT — roughly two to four periods in a row of getting better — in a part of the business that, until recently, had been giving investors little reason to expect it, AND that the causes of this young run are attached to the company itself and still in force?" We need to look for a part of the business that has been improving sequentially. Possibly clinical data? For CUDC-907, they reported at ASH in December 2015: 22 patients, 7 responses out of 16 evaluable. Now they have completed enrollment in monotherapy arm: 25 patients, 8 responses out of 19 evaluable. So that's an increase in response count and evaluable patients. But is that a "run of consecutive periods of improvement"? They had Phase 1 data, now updated. That's two data points? But it's not a business metric like sales. It's clinical trial results. The question might be about the company's progress in developing drugs. But the phrasing "part of the business" could be clinical pipeline. However, the improvement is not sequential in terms of periods; it's just an update on the same trial. Also, the improvement is not necessarily "real improvement" in business performance. The company is still losing money.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| OLPX | Olaplex Holdings, Inc. | Q4 2023 | 2024-02-29 | D |
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| GPRE | Green Plains Inc. | Q4 2023 | 2024-02-07 | F |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| BMBL | Bumble Inc. | Q3 2023 | 2023-11-07 | F |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| GOLD | Barrick Gold Corporation | Q3 2023 | 2023-11-02 | C |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| TEL | TE Connectivity Ltd. | Q4 2023 | 2023-11-01 | B |
| SBRA | Sabra Health Care REIT, Inc. | Q1 2023 | 2023-05-04 | B |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| PKOH | Park-Ohio Holdings Corp. | Q3 2022 | 2022-11-13 | B |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| LEG | Leggett & Platt, Incorporated | Q3 2021 | 2021-11-02 | C |
| UFI | Unifi, Inc. | Q4 2021 | 2021-08-07 | B |
| ESRT | Empire State Realty Trust, Inc. | Q2 2021 | 2021-07-29 | C+ |
| LRN | Stride, Inc. | Q1 2019 | 2018-10-23 | B |
| ORAN | Orange SA | Q2 2018 | 2018-07-26 | B |
| AVT | Avnet, Inc. | Q2 2018 | 2018-01-25 | B |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| SPR | Spirit AeroSystems Holdings, Inc. | Q1 2016 | 2016-04-29 | D |
WRBY · Q1 2024 → YESThe question is about whether management conveys a short, still-young run of consecutive periods of real improvement in a part of the business that was previously unimpressive, caused by company-speci...
ASB · Q1 2024 → YESThe question is about whether management conveys a short, still-young run of consecutive periods of real improvement in a part of the business that was previously unimpressive, caused by company-speci...
KOPN · Q4 2023 → YESThe question is about whether management conveys a short, still-young run of consecutive periods of real improvement in a part of the business that was previously unimpressive, caused by company-speci...